February 15, 2023
- History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
- Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
- Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
- How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
- What Makes Radioligand Therapy IND Strategy Fundamentally Different?
History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...
Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
Developing cancer therapies is an incredibly complex, costly, and highly regulated journey. To navigate this challenging terrain, pharmaceutical and ...
Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
Bone cancers and soft tissue sarcomas represent a diverse group of rare malignancies arising from mesenchymal tissues including bone, muscle, fat, ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
